Paulo
Correia de Sá
Menu
Menu
The main goal of TL5 – Clinical Translational on Drug Targets and Innovative Biomedicines is to identify and support multidisciplinary disease-oriented research projects and cutting-edge R&D programs in drug discovery and pharmacological, pharmaceutical, and biotechnological innovation, regenerative cell therapies, and personalised medicine.
Coordinated by Paulo Correia de Sá, this thematic line relies on the collaboration of experts from a broad spectrum of fundamental biomedicine and clinical specialities, which is critical for translating basic science discoveries into more effective therapeutic strategies and validating new disease biomarkers.
The core skills of TL5 are (i) high-precision biochemical/immunological/biopharmaceutical assays for drug screening and function optimisation, (ii) a complete panel of isolated cells and tissue-based “in vitro” assays for drug testing, including advanced functional bioimaging, (iii) biopharmaceutical expertise in innovative drug delivery systems, (iv) pharmacological, toxicological and genetic animal models of Human diseases for “in vivo” pre-clinical testing and (v) Clinical Pharmacology competences authorised to design and perform human clinical trials.
Paulo Correia de Sá coordinates RISE-Health’s TL5 – Clinical Translational on Drug Targets and Innovative Biomedicines.
He obtained his MD degree from ICBAS-University of Porto in 1988 and did his Medical Internship at the General Hospital of Santo António (Porto, 1989-90), becoming a specialist in Orthopedics and Traumatology (CHVN Gaia, 1994-99). He received PhD training (JNICT PhD studentship) in Biomedical Sciences – Pharmacology from 1991 to 94 at ICBAS-UP). At ICBAS, he was an Assistant Professor (2000-04) and Associate Professor (2004-07) and currently, he is a Full Professor. He is also a Guest Full Professor at the Faculty of Medicine of the University Eduardo Mondlane in Maputo, Mozambique.
Elected Director of the Laboratory of Pharmacology & Neurobiology, he accumulated this position with the Department of Immuno-Physiology and Pharmacology Direction from 2000 until 2019 and was re-elected in 2023. He has been the Vice-President of the Scientific Council of ICBAS-UP since 2022. He had worked in several other academic positions.
He was the Coordinator of the FCT Research Unit for Multidisciplinary Investigations in Biomedicine (UMIB) from 2005 to 2014. He was designated as the local Coordinator of the FCT Centre for Drug Discovery and Innovative Medicines U.Porto (MedInUP) in 2015. He served as President and Vice-president of the Portugal Pharmacological Society and was a member of the Board of the Portuguese Society of Neurosciences.
RISE-Health
Faculty of Medicine of the University of Porto
Alameda Prof. Hernâni Monteiro
4200-319 Porto
